Immunotherapy for lung cancer (CIMAvax - EGF) 

Contact us

Lung cancer is by far the leading cause of cancer death among men and women, accounting for almost 25% of all cancer deaths.

Comercializadora de Servicios Médicos Cubanos, S.A. offers a comprehensive treatment for people with non-small cell lung cancer in advanced stages (IIIB and IV) or stable disease, after the first line onco-specific treatment of chemotherapy or radiotherapy, with the therapeutic vaccine CIMAvax - EGF®, which is based on immunotherapy, a procedure that stimulates the body's immune system. Unlike other more aggressive treatments, immunotherapy allows a long-term treatment, without affecting the patient's quality of life.

The CIMAvax - EGF® vaccine is a scientific result of Cuban biotechnology, of great international prestige, with excellent benefits in Cuban patients and in many other countries. It is a very safe vaccine that improves survival.

The treatment requires admission with a companion. It is administered intra muscular. It consists of an induction phase that begins with the administration of the first five doses during 14 days and a maintenance phase that includes re-immunizations every 28 days, which will be maintained until the patient's condition allows it.

In the Cuban oncology services that offer this program, the patient is evaluated by multidisciplinary teams (nationally certified and internationally endorsed) made up of internists, radiologists, pathologists, hematologists, surgeons, among others, presided over by a clinical oncologist. These specialists are responsible for establishing, according to the diagnosis and stage of the cancer, the personalized treatment.

To begin treatment, you should contact the Coordination and Processing Center of Comercializadora de Servicios Médicos Cubanos, S.A. at You will be sent the medical program with its costs.